Program
Prog
Development
Dev
Status
Stat
Indication/ProjectInd/Proj
PreclinicalPre
Phase 1PH1
Phase 2Ph2
Phase 3Ph3
Worldwide RightsRights
Next Anticipated MilestoneNext
Camlipixant Refractory Chronic Cough (BID Formulation)
Camlipixant Refractory Chronic Cough (BID Formulation)

2H 2024: CALM-1 Topline Results

2025: CALM-2 Topline Results

Bellus Health

2H 2024: CALM-1 Topline Results

2025: CALM-2 Topline Results

Camlipixant Pharmacokinetics (QD Formulation)
Camlipixant Pharmacokinetics (QD Formulation)

Conduct a multiple dose study of the ER formulation

Bellus Health

Conduct a multiple dose study of the ER formulation

Camlipixant (BLU-5937):

Highly Selective P2X3 Antagonist Targeting Cough Hypersensitivity

BELLUS Health is developing camlipixant (BLU-5937), an investigational P2X3 antagonist, for the treatment of refractory chronic cough. Preclinical and clinical evidence have linked the P2X3 receptor and refractory chronic cough to a sensory nerve dysfunction that can lead to cough hypersensitivity. Camlipixant has the potential to address the significant unmet need for an efficacious, safe and well tolerated treatment for refractory chronic cough.

We have initiated the CALM Phase 3 clinical program (CALM-1 and CALM-2) in refractory chronic cough, with each trial evaluating the efficacy, safety and tolerability of camlipixant. CALM-1 and CALM-2 are running concurrently, and each will recruit approximately 675 adult participants with refractory chronic cough.

Role of P2X3   Clinical Trials

Camlipixant (BLU-5937) remains in development and has not been approved for commercialization. The clinical safety and effectiveness of camlipixant have not yet been fully established. The development of this product, and an investment in BELLUS Health common shares, involves a significant amount of risks. We invite you to review our Annual Information Form to learn more about these risk factors. A summary of these can also be reviewed here.